Wugen, Inc. is a clinical-stage biotechnology company focused on developing innovative allogeneic, off-the-shelf cell therapies for cancer treatment. Their primary product, WU-CART-007, is a CD7-targeted CAR-T cell therapy designed to treat hematological malignancies such as T cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL). This therapy utilizes CRISPR/Cas9 gene editing technology to delete the CD7 antigen and the T cell receptor alpha constant (TRAC) from healthy donor-derived T cells. This engineering approach prevents fratricide—where CAR-T cells attack each other—and mitigates the risk of graft-versus-host disease (GvHD), a common complication in traditional CAR-T therapies.

In addition to WU-CART-007, Wugen is also developing memory natural killer (NK) cell therapies aimed at treating solid tumors. The company emphasizes the importance of creating off-the-shelf therapies that can be readily available for patients, addressing critical medical needs for those with limited treatment options. Wugen's commitment to advancing cell therapy is further supported by the recent appointment of Cherry T. Thomas, M.D., as Chief Medical Officer, who brings extensive experience in clinical development and regulatory affairs to the team. The company has received several designations from the U.S. Food and Drug Administration, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track status, which facilitate the expedited development of promising therapies.

United States

Wugen is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies.

Wugen is based out of St. Louis, Missouri and San Diego, California.

Wugen

Company Details